Vulvar dysplasia – Diagnostics – Overview of Information and Clinical Research

Vulvar dysplasia, also known as vulvar intraepithelial neoplasia (VIN), involves abnormal changes in the skin cells of the vulva that can develop into cancer over time if left untreated. Early detection through careful examination and timely diagnosis can prevent progression to invasive disease, making understanding the diagnostic process essential for women’s health.

Introduction: Who Should Undergo Diagnostics and When to Seek Them

Vulvar dysplasia is a condition where abnormal skin changes occur on the vulva, the external female genitals. These changes are not cancer, but they represent a warning sign that cancer could develop in the future. Understanding when to seek medical attention and who should undergo diagnostic evaluation is crucial for preventing serious complications.^[1]

Women who notice any unusual changes in their vulvar area should consult a doctor promptly. The most common symptoms include persistent itching or burning sensations on the vulva, visible skin color changes ranging from white or grey to pink, reddish, or dark brown, skin thickening or new growths that may resemble warts, and cracks or ulcerations in the vulvar skin. Some women may also experience tingling, soreness, or discomfort during sexual intercourse.^[1]^[2]

However, not everyone with vulvar dysplasia experiences symptoms. Some women discover they have the condition during routine gynecologic examinations, which is why regular check-ups are important. This makes it especially crucial for women with risk factors to maintain regular medical visits even when they feel completely well.^[2]

Certain groups of women face higher risks and should be particularly vigilant. Women with a history of human papillomavirus (HPV) infection—a sexually transmitted virus—are at increased risk. The high-risk strains of HPV, particularly types 16, 18, and 33, are strongly associated with vulvar dysplasia. Women who smoke cigarettes also face elevated risk, as do those with a weakened immune system, which can occur due to conditions like HIV or medications that suppress immunity.^[1]^[2]

Another important risk factor is lichen sclerosus, a chronic inflammatory skin condition affecting the vulva. Women with this condition have a higher chance of developing a specific type of vulvar dysplasia called differentiated VIN, which tends to progress to cancer more quickly than other types. If you have lichen sclerosus, your doctor should monitor your vulva closely through regular examinations.^[1]^[2]

Women in their forties and fifties most commonly develop vulvar dysplasia, though it can occur at various ages. The type associated with HPV typically appears in younger women, sometimes even during adolescence, while the type related to chronic inflammation usually affects older women, particularly those over sixty.^[1]^[8]

If you have any of these risk factors, performing regular vulva self-checks at home can help you notice worrisome changes early. Stand with one foot elevated on a stool or the edge of the bathtub, and use a hand mirror to examine your vulvar area in good lighting. Look for any new growths, color changes, or areas that appear different from usual. If you notice anything concerning, schedule an appointment with your healthcare provider promptly.^[1]

⚠️ Important

Unlike cervical cancer, there are no screening strategies for early detection of vulvar dysplasia. Detection relies entirely on visual recognition during examinations and confirmation through biopsy. This means you should never ignore vulvar symptoms or skip regular gynecologic visits, especially if you have risk factors.^[5]^[7]

Diagnostic Methods

Diagnosing vulvar dysplasia involves several steps, starting with a thorough examination and progressing to more detailed testing when necessary. The diagnostic process aims to identify abnormal cells, determine their severity, and distinguish vulvar dysplasia from other vulvar conditions that may cause similar symptoms.

Physical Examination

The diagnostic journey typically begins when you visit your doctor with symptoms or during a routine gynecologic exam. Your healthcare provider will ask detailed questions about your symptoms, including when they started, how long they have lasted, and whether anything makes them better or worse. They will also inquire about your sexual history, smoking habits, and any previous diagnoses of HPV or other vulvar conditions.^[2]

During the physical examination, your doctor will carefully inspect your entire vulvar area. They will look for visible skin changes, including areas of discoloration, new growths, thickened patches, or any unusual texture. The appearance of vulvar dysplasia can vary considerably. Some lesions appear as raised bumps, while others are flat. The color may range from white or grey to red, pink, brown, or even black. Changes might affect just one small area or appear in multiple locations across the vulva.^[2]^[5]

Your doctor will gently touch the affected areas to assess texture and tenderness. They may also examine your inguinal lymph nodes, which are located in your groin area, to check for any swelling that might suggest the condition has spread beyond the vulvar skin.^[1]

Colposcopy

If your doctor identifies suspicious areas during the initial examination, they may perform a colposcopy. This procedure uses a special magnifying instrument called a colposcope to examine your vulva more closely. The colposcope does not touch your body—it remains positioned outside while providing a magnified view of your skin.^[5]

Colposcopy helps your doctor see details that might not be visible to the naked eye. The magnification allows them to identify abnormal patterns in the skin, unusual blood vessel formations, and clearly define the borders of suspicious lesions. This detailed visualization helps determine the best locations for taking tissue samples and assesses the extent of the abnormal areas.^[4]^[5]

During colposcopy, your doctor may apply dilute acetic acid (similar to vinegar) to your vulvar skin. This solution temporarily highlights abnormal areas by causing them to appear white or more distinct, making them easier to identify and evaluate. This technique helps guide the biopsy process.^[8]

Biopsy

A biopsy is the only definitive way to diagnose vulvar dysplasia. During this procedure, your doctor removes a small sample of tissue from the suspicious area to examine under a microscope. The biopsy is essential because many different conditions can cause similar-looking changes on the vulva, and only microscopic examination can determine whether abnormal cells are present and how severe the changes are.^[1]^[5]

Before taking the biopsy, your doctor will numb the area with a local anesthetic injection. You may feel a brief pinch or sting when the numbing medicine is administered, but the biopsy itself should not be painful once the area is numb. The doctor will use a small instrument to remove one or more tiny pieces of tissue from the affected areas. If multiple suspicious spots are present, several biopsies may be taken from different locations.^[1]

The tissue samples are then sent to a laboratory where a pathologist—a doctor who specializes in examining cells and tissues—studies them under a microscope. The pathologist looks for abnormal cells, determines how deeply they penetrate into the skin layers, and classifies the type and severity of dysplasia present.^[1]

Your doctor may perform the biopsy during your initial visit or schedule it for a separate appointment. In some cases, if the examination findings are particularly concerning, the biopsy might be done under general anesthesia in an operating room, especially if your doctor suspects that hidden cancer might be present beneath the surface changes.^[1]

Understanding Biopsy Results

Biopsy results typically take about two weeks to return from the laboratory. These results are crucial because they tell you exactly what type of vulvar dysplasia you have and guide your treatment plan. The classification system has evolved over the years, and you may encounter different terminology depending on when your diagnosis was made.^[1]^[6]

The current classification system divides vulvar dysplasia into two main categories: usual type VIN (uVIN), also called high-grade squamous intraepithelial lesion (HSIL), and differentiated VIN (dVIN). There is also a less serious category called low-grade squamous intraepithelial lesion (LSIL), which is associated with low-risk HPV types and rarely progresses to cancer. LSIL often resolves on its own without treatment.^[2]^[6]

Usual type VIN (HSIL) is the most common form, accounting for the majority of cases. This type is strongly linked to high-risk HPV infections and typically develops in women during their forties. If left untreated, it usually takes six to seven years to progress to invasive cancer, though this timeline varies among individuals.^[2]^[8]

Differentiated VIN is less common, representing only about five percent of vulvar dysplasia cases. This type usually affects older women, particularly those over sixty, and is associated with chronic inflammatory conditions like lichen sclerosus rather than HPV infection. Differentiated VIN carries a higher risk of progressing to cancer and does so more quickly—typically within two to three years—making prompt treatment especially important.^[2]^[8]

Older classification systems used terms like VIN 1, VIN 2, and VIN 3, based on how deeply the abnormal cells penetrated into the skin layers. You may still encounter these terms in older medical records. VIN 1 corresponded to what is now called LSIL, while VIN 2 and VIN 3 both fall under the current category of HSIL or usual type VIN.^[6]^[8]

Additional Testing

In most cases, physical examination, colposcopy, and biopsy provide sufficient information for diagnosis. However, if your biopsy results are unclear or if there is concern that cancer might already be present, your doctor may recommend additional tests to gather more information about your condition.^[4]

Persistent lesions that do not respond to initial treatments, rapidly changing areas, lesions with atypical vascular patterns or unusual colors or borders, and suspected genital warts in postmenopausal women should all be biopsied. These characteristics suggest a higher likelihood of more serious disease and require careful evaluation.^[4]

One important point to remember is that healthcare providers should maintain a low threshold for performing biopsies when evaluating vulvar lesions. It is better to biopsy a benign lesion than to miss an early cancer or high-grade dysplasia. The biopsy procedure is relatively simple and low-risk, while delayed diagnosis can lead to much more serious consequences.^[4]

Diagnostics for Clinical Trial Qualification

Women with vulvar dysplasia may have opportunities to participate in clinical trials—research studies testing new treatments or comparing different treatment approaches. Clinical trials follow strict guidelines to ensure patient safety and generate reliable scientific information. To determine whether you are eligible to participate in a specific trial, researchers use standardized diagnostic criteria.^[15]

The qualification process for clinical trials typically begins with the same diagnostic procedures used in routine clinical care: physical examination, colposcopy, and biopsy confirmation of vulvar dysplasia. However, clinical trials often have additional specific requirements that must be documented before enrollment.^[15]

Most clinical trials require precise classification of your vulvar dysplasia type and grade. The biopsy report must clearly state whether you have high-grade squamous intraepithelial lesion (HSIL), differentiated VIN, or low-grade squamous intraepithelial lesion (LSIL). Some trials may only accept patients with specific types or grades of dysplasia, while excluding others. This specificity ensures that researchers can accurately evaluate how well a treatment works for a particular condition.^[7]^[8]

The size, location, and number of dysplastic lesions often factor into eligibility criteria. Researchers may measure lesion dimensions during colposcopy and document their precise anatomical locations. Some trials may focus on single lesions, while others specifically study treatments for multiple or widespread dysplastic areas. Photographic documentation of lesions may be required both for enrollment and to track changes during the study.^[4]

Clinical trials commonly require that biopsies definitively rule out invasive cancer. This is crucial because treatments being tested for precancerous dysplasia may not be appropriate for invasive cancer. If your biopsy shows any signs of invasion—meaning abnormal cells have broken through the basement membrane into deeper tissues—you would not qualify for most dysplasia treatment trials. Instead, you would need treatment specifically designed for cancer.^[7]

Some trials have specific requirements regarding HPV status. They may require testing to confirm the presence or absence of high-risk HPV types, particularly HPV-16, which is most commonly associated with usual type VIN. HPV testing uses either tissue samples from your biopsy or swabs collected from the vulvar surface. Knowing your HPV status helps researchers understand whether HPV-targeted treatments might be effective.^[2]^[8]

Your overall health status influences clinical trial eligibility as well. Many trials exclude patients with certain medical conditions, particularly those affecting immune function, because these conditions can influence how dysplasia develops and responds to treatment. You may need blood tests to assess your immune system function, liver and kidney function, and overall health before enrollment. Women who are pregnant or might become pregnant during the study are typically excluded from clinical trials due to potential risks to the developing baby.^[7]

Previous treatment history also matters for many clinical trials. Some studies specifically recruit patients who have never received treatment for their dysplasia, while others focus on women whose dysplasia has returned after previous treatment. You may need to provide detailed medical records documenting any prior vulvar surgeries, laser treatments, or topical therapies. The time elapsed since previous treatments may also affect eligibility.^[4]^[5]

Age restrictions apply to some clinical trials. While vulvar dysplasia can occur in women of various ages, certain studies may focus on specific age groups to understand how treatments work in different populations. For example, a trial might specifically study younger women with HPV-related dysplasia or focus on older women with inflammation-related disease.^[8]

⚠️ Important

Participating in a clinical trial does not mean you will definitely receive experimental treatment. Many trials use a comparison approach where some participants receive the new treatment being studied while others receive standard treatment or a placebo. The assignment is usually random, and neither you nor your doctor can choose which group you join. This approach is necessary to determine whether new treatments truly work better than existing options.^[15]

If you are interested in clinical trials, discuss this with your healthcare provider. They can help you understand which trials might be appropriate for your specific situation and guide you through the enrollment process. Keep in mind that clinical trial participation is entirely voluntary, and you can withdraw at any time if you change your mind or experience problems.^[15]

Prognosis and Survival Rate

Prognosis

The outlook for women with vulvar dysplasia is generally very good when the condition is detected early and treated appropriately. Most cases of vulvar intraepithelial neoplasia can be cured with proper treatment and follow-up care. The key to a favorable outcome lies in preventing progression to invasive cancer through timely intervention.^[1]

The prognosis varies depending on the type of dysplasia present. Usual type VIN (high-grade squamous intraepithelial lesion) associated with HPV typically takes six to seven years to progress to invasive cancer if left completely untreated. This relatively slow progression provides a substantial window of opportunity for detection and treatment. However, differentiated VIN, which is associated with chronic inflammatory conditions like lichen sclerosus, progresses more rapidly—usually within two to three years—making prompt treatment especially critical for this type.^[2]

Several factors influence individual prognosis. Women with positive margins following surgical excision—meaning abnormal cells were found at the edges of the removed tissue—face higher recurrence rates. Cigarette smoking is strongly associated with increased recurrence risk and poorer outcomes. Having multiple dysplastic lesions rather than a single lesion also increases the likelihood of recurrence. Women with weakened immune systems, whether due to HIV infection, organ transplantation, or immunosuppressive medications, tend to have more persistent disease and higher recurrence rates.^[5]^[13]

Recurrence rates after treatment range from nine to fifty percent across all treatment methods, highlighting the importance of long-term monitoring. Women with vulvar dysplasia remain at risk for recurrent disease throughout their lifetime, even after successful treatment. This ongoing risk underscores the necessity of regular follow-up examinations and self-monitoring.^[5]^[18]

The progression from vulvar dysplasia to invasive cancer is not inevitable. Many women never develop cancer if their dysplasia is properly treated and monitored. Low-grade squamous intraepithelial lesions (LSIL) associated with low-risk HPV types rarely become cancerous and often resolve spontaneously without any treatment. Even high-grade lesions can be effectively managed when detected early.^[2]^[6]

After successful treatment, women who have no new lesions at their six-month and twelve-month follow-up visits can typically transition to annual monitoring by visual inspection. This relatively slow progression rate allows for practical long-term surveillance without requiring frequent invasive procedures. However, any new symptoms or visible changes between scheduled appointments should prompt immediate evaluation.^[5]^[7]

Survival Rate

Survival rates specifically for vulvar dysplasia itself are not typically reported because dysplasia is a precancerous condition rather than cancer. Women with vulvar dysplasia who receive appropriate treatment have excellent survival rates, as the condition can be cured before it becomes life-threatening cancer.^[1]

However, survival statistics become relevant when discussing vulvar cancer, which can develop if dysplasia progresses untreated. For women who develop invasive vulvar cancer, prognosis depends heavily on whether the cancer has spread to lymph nodes. Patients with operable vulvar cancer that has not spread to lymph nodes have an overall survival rate of approximately ninety percent. When cancer has spread to the lymph nodes, the five-year survival rate drops to approximately fifty to sixty percent. This dramatic difference emphasizes why preventing progression from dysplasia to invasive cancer through early detection and treatment is so important.^[15]

The incidence of vulvar dysplasia has increased significantly over recent decades. According to surveillance data, vulvar intraepithelial neoplasia is now four times more common than it was in the 1970s, largely due to rising HPV infection rates. Despite this increase in dysplasia cases, most women with properly treated dysplasia never develop cancer, demonstrating the effectiveness of early intervention.^[1]

Women diagnosed with vulvar dysplasia should understand that while the condition requires ongoing attention and may cause concern, it represents an opportunity to prevent cancer rather than a cancer diagnosis itself. With appropriate treatment and diligent follow-up care, the vast majority of women with vulvar dysplasia can expect normal life expectancy and quality of life.^[1]

#1 Clinical Trials Search in Europe